TScan Therapeutics TCRX
NASDAQ TCRX
$0.14 -0.01 (-6.67%)
At close: Nov 19, 2026 · 4:00 PM EST

TScan Therapeutics (TCRX) Cash & Equivalents (2020 - 2026)

Updated

TScan Therapeutics (TCRX) recorded Cash & Equivalents of $73.04 million in Q3 2026, down 56.9% from $169.51 million a year earlier and down 27.1% from the prior quarter.

Analysis

TScan Therapeutics (TCRX) Cash & Equivalents (2020 - 2026) Analysis & Trends

At the end of FY2025, TScan Therapeutics reported Cash & Equivalents of $152.41 million, down 14.7% from FY2024.

  • Annual Cash & Equivalents has a five-year compound annual growth rate of 34.4% (FY2020 to FY2025).
  • Across earlier years, Cash & Equivalents came in at $178.69 million in FY2024 (+34.0%), $133.36 million in FY2023 (+11.1%), $120.03 million in FY2022 (-25.6%) and $161.41 million in FY2021 (+363.9%).
  • The Q3 2026 figure is the lowest quarterly Cash & Equivalents since Q4 2020.
  • On a year-over-year basis, Cash & Equivalents has declined for four consecutive quarters, with an average decline of 11.1% over the last eight quarters.
  • Peak year-over-year performance for Cash & Equivalents in the last five years was growth of 363.9% in Q4 2021, against a decline of 56.9% in Q3 2026 at the low end.
  • Per Business Quant, the preceding three quarters came in at $100.2 million (Q2 2026), $128.06 million (Q1 2026) and $152.41 million (Q4 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. (Qtr)
1 PetVivo Holdings 3,096.39 Bn 3,096.39 Bn 196,075.00 16,287.00
2 Eli Lilly 1,202.70 Bn 1,176.32 Bn 20.46 Bn 4.89 Bn
3 Johnson & Johnson 649.77 Bn 569.63 Bn 17.30 Bn 16.91 Bn
4 AbbVie 507.00 Bn 475.00 Bn 13.12 Bn 10.77 Bn
5 Merck 329.70 Bn 292.64 Bn 13.19 Bn 9.55 Bn
6 Novartis Ag 291.91 Bn 265.14 Bn - 400.00 Mn
7 Amgen 236.26 Bn 187.91 Bn 7.58 Bn 13.19 Bn
8 Gilead Sciences 207.15 Bn 182.26 Bn 6.73 Bn 6.44 Bn
9 Gsk 193.54 Bn 176.38 Bn - 3.88 Bn
10 TScan Therapeutics 18.87 Mn -434.83 Mn - 73.04 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 73.04 Mn
Jun 30, 2026 100.20 Mn
Mar 31, 2026 128.06 Mn
Dec 31, 2025 152.41 Mn
Sep 30, 2025 169.51 Mn
Jun 30, 2025 169.39 Mn
Mar 31, 2025 154.11 Mn
Dec 31, 2024 178.69 Mn
Sep 30, 2024 133.12 Mn
Jun 30, 2024 242.16 Mn
Mar 31, 2024 140.51 Mn
Dec 31, 2023 133.36 Mn
Sep 30, 2023 155.19 Mn
Jun 30, 2023 208.84 Mn
Mar 31, 2023 95.61 Mn
Dec 31, 2022 120.03 Mn
Sep 30, 2022 137.31 Mn
Jun 30, 2022 125.60 Mn
Mar 31, 2022 140.84 Mn
Dec 31, 2021 161.41 Mn
API Access

TScan Therapeutics Cash & Equivalents API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=TCRX&period=max&api_key=YOUR_API_KEY